XLON
POLX
Market cap1mUSD
Dec 22, Last price
0.08GBP
Name
Polarean Imaging PLC
Chart & Performance
P/E
—
P/S
0.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
47.56%
Rev. gr., 5y
6.07%
Revenues
2m
+171.42%
Net income
-7m
L-43.77%
CFO
-6m
L-46.26%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Polarean Imaging plc is a medical technology company specializing in drug-device combinations, catering to the medical imaging industry across the U.S., Canada, Germany, and the U.K. Its core business involves the creation and market introduction of gas polarizer apparatus and their supporting accessories. Polarean crafts innovative equipment designed to upgrade conventional magnetic resonance imaging (MRI) scanners for detailed functional pulmonary assessment. A significant area of expertise is the application of hyperpolarized xenon gas (129Xe) as a unique imaging tracer. This allows for precise, regional visualization of ventilation and gas exchange within the lungs' most intricate airways, the vital tissue interface separating the lungs from the bloodstream, and the pulmonary vascular network, thereby presenting a groundbreaking diagnostic methodology. Additionally, the firm undertakes the design and production of specialized MRI radiofrequency coils, essential components for conducting 129Xe imaging within an MRI framework. Established in 2016, Polarean Imaging plc has its operational base in Durham, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||